Participants 121 149 4
acute promyelocytic leukemia
Participants 199 233 4
acute promyelocytic leukemia (APL)
Participants 703 883 6
previously untreated adult APL patients registered to protocol INT 0129 by the Eastern Cooperative Oncology Group, the Southwest Oncology Group, and the Cancer and Leukemia Group B
Participants 885 1098 8
Of 279 clinically eligible cases, 230 were molecularly evaluable, and of these, 111 were randomized to receive remission induction therapy with all-trans retinoic acid (ATRA) and 119 with conventional chemotherapy
Participants 2419 2431 4
APL patients
